Clinical Cooperations

Translational Research at Helmholtz Zentrum München

The objective of translational research is to transfer knowlegde that has been acquired by basic research into practical use and turn it into innovation. Successful project development essentially relies on a value driven cooperation of different disciplines and a close exchange between basic scientists and clinicians.


Source: Halfpoint/ Fotolia

This interdisciplinary research approach is realized within Translational Research Centers and the following Clinical Cooperations:

 

 

Diabetes

Nutrigenomics and Type-2-Diabetes mellitus

Genetic risk variants for type-2-diabetes and obesity are functionally characterized to open up new strategies to prevent and treat type-2-diabetes and obesity.

Partner Institutions: Helmholtz Zentrum München, Technische Universität München, University Hospital rechts der Isar

Head: Prof. Dr. Hans Hauner
Tel. +49 8161 71-2000

 

More information about CCG Nutrigenomics and Type-2-Diabetes mellitus

Biomarkers for the Subclassification of Type-2-Diabetes

Identification and validation of biomarkers to indicate an increased risk for type-2-diabetes in individuals with normal glucose metabolism.

Partner Institutions: Helmholtz Zentrum München, LMU University Hospital

Head: Prof. Dr. Jochen Seißler
Tel. +49 89 5160-2200

 

More information about CCG Biomarkers for Subclassification of Type-2-Diabetes


Allergy

Clinical Allergology Unit

A birth cohort investigates the interactions and influences of the microbiome, the immune system along with environmental factors in the development of allergic diseases.

Partner Institutions:
Helmholtz Zentrum München, University Hospital rechts der Isar

Head: Univ.-Prof. Dr. med. Tilo Biedermann
Tel. +49 89 4140-3170



More Information about Clinical Allergy Unit (EKA)


Innovative Therapies

Personalized Radiotherapy in Head and Neck Cancer

Identification and validation of biomarkers of radiation sensitivity in HNSCC, in order to allow a stratification of patients prior to treatment for an improvement of personalized therapy concepts.

Partner Institutions: Helmholtz Zentrum München, LMU University Hospital.

Head: Prof. Dr. med. Claus Belka
Tel. +49 89 4400-74520

More information about CCG Personalized Radiotherapy in Head and Neck Cancer

Clinical Pharmacology Unit

The immune response in a prospective observational cohort study after yellow fever vaccination is analysed. This approach is designed to identify genetic or phenotypic biomarkers that could predict the efficacy of yellow fever vaccination.

Partner Institutions: Helmholtz Zentrum München, LMU University Hospital

Head: Prof. Dr. med. Stefan Endres
Tel. +49 89 4400-57300

More information about the Unit Clinical Pharmacology

We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.